Sandra Pavey

Sandra Pavey

Auto-generated profile, based on publicly available information

Sandra Pavey

School of Medicine, The University of Queensland, Brisbane, Australia

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JDJonathan R. Dry
Jonathan R. Dry
SPSandra Pavey
Sandra Pavey
CPChristine A. Pratilas
Christine A. Pratilas
CHChris Harbron
Chris Harbron
SRSarah Runswick
Sarah Runswick
PSPaul D. Smith
Paul D. Smith
Selumetinib (AZD6244, ARRY-142886) is a selective, non–ATP-competitive inhibitor of mitogen-activated protein/extracellular signal–regulated kinase kinase (MEK)-1/2. The range of antitumor activity seen preclinically and in patients highlights the importance of identifying determinants of response to this drug. In large tumor cell panels of diverse lineage, we show that MEK inhibitor response does not have an absolute correlation with mutational or phospho-protein markers of BRAF/MEK, RAS, or phosphoinositide 3-kinase (PI3K) activity. We aimed to enhance predictivity by measuring pathway output through coregulated gene networks displaying differential mRNA expression exclusive to resistant cell subsets and correlated to mutational or dynamic pathway activity. We discovered an 18-gene signature enabling measurement of MEK functional output independent of tumor genotype. Where the MEK pathway is activated but the cells remain resistant to selumetinib, we identified a 13-gene signature that implicates the existence of compensatory signaling from RAS effectors other than PI3K. The ability of these signatures to stratify samples according to functional activation of MEK and/or selumetinib sensitivity was shown in multiple independent melanoma, colon, breast, and lung tumor cell lines and in xenograft models. Furthermore, we were able to measure these signatures in fixed archival melanoma tumor samples using a single RT-qPCR–based test and found intergene correlations and associations with genetic markers of pathway activity to be preserved. These signatures offer useful tools for the study of MEK biology and clinical application of MEK inhibitors, and the novel approaches taken may benefit other targeted therapies. Cancer Res; 70(6); 2264–73

31 May 2005 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
WZW Zuidervaart
W Zuidervaart
FNF van Nieuwpoort
F van Nieuwpoort
MSM Stark
M Stark
RDR Dijkman
R Dijkman
LPL Packer
L Packer
NGN A Gruis
N A Gruis
In contrast to cutaneous melanoma, there is no evidence that BRAF mutations are involved in the activation of the mitogen-activated protein kinase (MAPK) pathway in uveal melanoma, although there is increasing evidence that this pathway is activated frequently in the latter tumours. In this study, we performed mutation analysis of the RAS and BRAF genes in a panel of 11 uveal melanoma cell lines and 19 primary uveal melanoma tumours. In addition, Western blot and immunohistochemical analyses were performed on downstream members of the MAPK pathway in order to assess the contribution of each of these components. No mutations were found in any of the three RAS gene family members and only one cell line carried a BRAF mutation (V599E). Despite this, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK), ERK and ELK were constitutively activated in all samples. These data suggest that activation of the MAPK pathway is commonly involved in the development of uveal melanoma, but occurs through a mechanism different to that of cutaneous melanoma.

29 March 2004 in Oncogene
Verified
Journal Article
Closed access
PDF file
SPSandra Pavey
Sandra Pavey
PJPeter Johansson
Peter Johansson
LPLeisl Packer
Leisl Packer
JTJennifer Taylor
Jennifer Taylor
MSMitchell Stark
Mitchell Stark
NHNicholas K Hayward
Nicholas K Hayward

27 March 2002 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
DWDavid C. Whiteman
David C. Whiteman
XZXiao‐Ping Zhou
Xiao‐Ping Zhou
MCMargaret C. Cummings
Margaret C. Cummings
SPSandra Pavey
Sandra Pavey
NHNicholas K. Hayward
Nicholas K. Hayward
CECharis Eng
Charis Eng

15 May 2007 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JLJill E. Larsen
Jill E. Larsen
SPSandra J. Pavey
Sandra J. Pavey
LPLinda H. Passmore
Linda H. Passmore
RBRayleen V. Bowman
Rayleen V. Bowman
NHNicholas K. Hayward
Nicholas K. Hayward
KFKwun M. Fong
Kwun M. Fong
Purpose: Improving outcomes for early-stage lung cancer is a major research focus at present because a significant proportion of stage I patients develop recurrent disease within 5 years of curative-intent lung resection. Within tumor stage groups, conventional prognostic indicators currently fail to predict relapse accurately. Experimental Design: To identify a gene signature predictive of recurrence in primary lung adenocarcinoma, we analyzed gene expression profiles in a training set of 48 node-negative tumors (stage I-II), comparing tumors from cases who remained disease-free for a minimum of 36 months with those from cases whose disease recurred within 18 months of complete resection. Results: Cox proportional hazards modeling with leave-one-out cross-validation identified a 54-gene signature capable of predicting risk of recurrence in two independent validation cohorts of 55 adenocarcinomas [log-rank P = 0.039; hazard ratio (HR), 2.2; 95% confidence interval (95% CI), 1.1-4.7] and 40 adenocarcinomas (log-rank P = 0.044; HR, 3.3; 95% CI, 1.4-7.9). Kaplan-Meier log-rank analysis found that predicted poor-outcome groups had significantly shorter survival, and furthermore, the signature predicted outcome independently of conventional indicators of tumor stage and node stage. In a subset of earliest stage adenocarcinomas, generally expected to have good outcome, the signature predicted samples with significantly poorer survival. Conclusions: We describe a 54-gene signature that predicts the risk of recurrent disease independently of tumor stage and which therefore has potential to refine clinical prognosis for patients undergoing resection for primary adenocarcinoma of the lung.

5 March 2012 in Oncogene
Verified
Journal Article
Open access
PDF file
KBK Brooks
K Brooks
VOV Oakes
V Oakes
BEB Edwards
B Edwards
MRM Ranall
M Ranall
PLP Leo
P Leo
Brian GabrielliBrian Gabrielli
Brian Gabrielli
There are few effective treatments for metastatic melanoma. Checkpoint kinase 1 (Chk1) inhibitors are being trialled for their efficacy in enhancing conventional chemotherapeutic agents, but their effectiveness as single agents is not known. We have examined the effectiveness of two novel Chk1 selective inhibitors, AR323 and AR678, in a panel of melanoma cell lines and normal cell types. We demonstrate that these drugs display single-agent activity, with IC50s in the low nanomolar range. The drugs produce cytotoxic effects in cell lines that are most sensitive to these drugs, whereas normal cells are only sensitive to these drugs at the higher concentrations where they have cytostatic activity. The cytotoxic effect is the consequence of inhibition of S-phase Chk1, which drives cells prematurely from late S phase into an aberrant mitosis and results in either failure of cytokinesis or cell death through an apoptotic mechanism. The sensitivity to the Chk1 inhibitors was correlated with the level of endogenous DNA damage indicating replicative stress. Chk1 inhibitors are viable single-agent therapies that target melanoma cells with high levels of endogenous DNA damage. This sensitivity suggests that Chk1 is a critical component of an adaptation to replicative stress in these cells. It also suggests that markers of DNA damage may be useful in identifying the melanomas and potentially other tumour types that are more likely to be sensitive to Chk1 inhibitors as single agents.